David Dejardin

823 total citations
28 papers, 559 citations indexed

About

David Dejardin is a scholar working on Genetics, Hematology and Statistics and Probability. According to data from OpenAlex, David Dejardin has authored 28 papers receiving a total of 559 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Genetics, 12 papers in Hematology and 8 papers in Statistics and Probability. Recurrent topics in David Dejardin's work include Chronic Lymphocytic Leukemia Research (12 papers), Chronic Myeloid Leukemia Treatments (12 papers) and Statistical Methods in Clinical Trials (7 papers). David Dejardin is often cited by papers focused on Chronic Lymphocytic Leukemia Research (12 papers), Chronic Myeloid Leukemia Treatments (12 papers) and Statistical Methods in Clinical Trials (7 papers). David Dejardin collaborates with scholars based in Belgium, United States and Switzerland. David Dejardin's co-authors include Emmanuel Lesaffre, Hagop M. Kantarjian, Jörge E. Cortes, Joost van Rosmalen, Jerzy Hołowiecki, Ricardo Pasqüini, Yvette van Norden, Nelson Hamerschlak, Eric Bleickardt and Bob Löwenberg and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

David Dejardin

27 papers receiving 533 citations

Peers

David Dejardin
Tuochuan Dong United States
Paul M. Diderichsen United States
Alice Huntsman-Labed United States
Herbert Struemper United States
Junshan Qiu United States
John H. Moon United States
Jonathon Vallejo United States
Jon Ukropec United States
Matteo B. Suter Italy
Jeanne Fourie Zirkelbach United States
Tuochuan Dong United States
David Dejardin
Citations per year, relative to David Dejardin David Dejardin (= 1×) peers Tuochuan Dong

Countries citing papers authored by David Dejardin

Since Specialization
Citations

This map shows the geographic impact of David Dejardin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Dejardin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Dejardin more than expected).

Fields of papers citing papers by David Dejardin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Dejardin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Dejardin. The network helps show where David Dejardin may publish in the future.

Co-authorship network of co-authors of David Dejardin

This figure shows the co-authorship network connecting the top 25 collaborators of David Dejardin. A scholar is included among the top collaborators of David Dejardin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Dejardin. David Dejardin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Dejardin, David, et al.. (2024). An overview of statistical methods for biomarkers relevant to early clinical development of cancer immunotherapies. Frontiers in Immunology. 15. 1351584–1351584. 1 indexed citations
2.
Dejardin, David, Bo Huang, Ying Yuan, et al.. (2024). Dose Optimization for Novel Oncology Agents: Design Options and Strategies. Statistics in Biopharmaceutical Research. 16(3). 326–337. 3 indexed citations
3.
Steeghs, Neeltje, Carlos Gomez‐Roca, Kristoffer Staal Rohrberg, et al.. (2024). Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity from a Phase I Study of Simlukafusp Alfa (FAP-IL2v) in Advanced/Metastatic Solid Tumors. Clinical Cancer Research. 30(13). 2693–2701. 11 indexed citations
4.
Dejardin, David, Anton Kraxner, Annika Blank, et al.. (2023). A Composite Decision Rule of CD8+ T-cell Density in Tumor Biopsies Predicts Efficacy in Early-stage, Immunotherapy Trials. Clinical Cancer Research. 30(4). 877–882. 4 indexed citations
5.
Dejardin, David, et al.. (2023). Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data. Journal for ImmunoTherapy of Cancer. 11(2). e006464–e006464. 20 indexed citations
6.
Hansen, Aaron R., Carlos Gomez‐Roca, Martijn P. Lolkema, et al.. (2021). 906P Simlukafusp α and cetuximab combination in patients with recurrent, unresectable or metastatic squamous cell carcinoma of the head and neck. Annals of Oncology. 32. S805–S805. 3 indexed citations
7.
Rosmalen, Joost van, et al.. (2018). Modified power prior with multiple historical trials for binary endpoints. Statistics in Medicine. 38(7). 1147–1169. 34 indexed citations
8.
Rosmalen, Joost van, David Dejardin, Yvette van Norden, Bob Löwenberg, & Emmanuel Lesaffre. (2017). Including historical data in the analysis of clinical trials: Is it worth the effort?. Statistical Methods in Medical Research. 27(10). 3167–3182. 89 indexed citations
9.
10.
Dejardin, David, Emmanuel Lesaffre, Paul Hamberg, & Jaap Verweij. (2014). A randomized phase I Bayesian dose escalation design for the combination of anti‐cancer drugs. Pharmaceutical Statistics. 13(3). 196–207. 4 indexed citations
11.
Dejardin, David & Emmanuel Lesaffre. (2013). Stochastic EM algorithm for doubly interval-censored data. Biostatistics. 14(4). 766–778. 7 indexed citations
12.
Dejardin, David. (2013). Statistical Models for the Analysis of Oncology Endpoints. 1 indexed citations
13.
Shah, Neil P., Hagop M. Kantarjian, Dong‐Wook Kim, et al.. (2012). Six-year (yr) follow-up of patients (pts) with imatinib-resistant or -intolerant chronic-phase chronic myeloid leukemia (CML-CP) receiving dasatinib.. Journal of Clinical Oncology. 30(15_suppl). 6506–6506. 31 indexed citations
14.
Khoury, H. Jean, Jörge E. Cortes, Hagop M. Kantarjian, et al.. (2010). Safety and Efficacy of Dasatinib (DAS) Vs. Imatinib (IM) by Baseline Comorbidity In Patients with Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Analysis of the DASISION Trial.. Blood. 116(21). 3421–3421. 14 indexed citations
15.
Dejardin, David, Emmanuel Lesaffre, & Geert Verbeke. (2010). Joint modeling of progression‐free survival and death in advanced cancer clinical trials. Statistics in Medicine. 29(16). 1724–1734. 13 indexed citations
16.
17.
Schiffer, CA, Jörge E. Cortes, Giuseppe Saglio, et al.. (2010). Association of lymphocytosis following treatment with dasatinib with response and outcome.. Journal of Clinical Oncology. 28(15_suppl). 6553–6553. 7 indexed citations
18.
Kantarjian, Hagop M., Ricardo Pasqüini, Vincent Lévy, et al.. (2009). Dasatinib or high‐dose imatinib for chronic‐phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily. Cancer. 115(18). 4136–4147. 167 indexed citations
19.
Shah, Neha, P Rousselot, Ricardo Pasqüini, et al.. (2006). Dasatinib (D) vs high dose imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP-CML) resistant to imatinib. Results of CA180017 START-R randomized trial. Journal of Clinical Oncology. 24(18_suppl). 6507–6507. 16 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tuochuan Dong Breakdown of academic impact, for papers by Paul M. Diderichsen Breakdown of academic impact, for papers by Alice Huntsman-Labed Breakdown of academic impact, for papers by Herbert Struemper Breakdown of academic impact, for papers by Junshan Qiu Breakdown of academic impact, for papers by John H. Moon Breakdown of academic impact, for papers by Jonathon Vallejo Breakdown of academic impact, for papers by Jon Ukropec Breakdown of academic impact, for papers by Matteo B. Suter Breakdown of academic impact, for papers by Jeanne Fourie Zirkelbach
Rankless by CCL
2026